TrialThe oncologist2019

Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.

Samuel J Klempner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.